Nexalin Technology (NASDAQ:NXL) Receives “Hold” Rating from Maxim Group

Nexalin Technology (NASDAQ:NXL)‘s stock had its “hold” rating reiterated by equities researchers at Maxim Group in a research report issued to clients and investors on Thursday,Benzinga reports.

Nexalin Technology Price Performance

Shares of NXL opened at $4.36 on Thursday. The stock has a market capitalization of $56.08 million, a PE ratio of -6.81 and a beta of 3.78. The business’s fifty day moving average price is $2.59 and its 200 day moving average price is $1.60. Nexalin Technology has a 12-month low of $0.25 and a 12-month high of $4.49.

Nexalin Technology (NASDAQ:NXL) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.23) EPS for the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%. The business had revenue of $0.04 million during the quarter.

Institutional Investors Weigh In On Nexalin Technology

An institutional investor recently bought a new position in Nexalin Technology stock. CVI Holdings LLC bought a new stake in Nexalin Technology, Inc. (NASDAQ:NXL) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 55,462 shares of the company’s stock, valued at approximately $94,000. CVI Holdings LLC owned 0.52% of Nexalin Technology at the end of the most recent reporting period. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.